Tacrolimus in refractory juvenile dermatomyositis: Case report and review of literature

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Juvenile dermatomyositis (JDM) is the most common type of inflammatory myositis in childhood, characterized by proximal muscle weakness and rash. The standard treatment of JDM involves steroids and methotrexate (MTX). A small proportion of patients do not respond to steroids and MTX. We present a couple of patients with refractory JDM who had failed to respond to steroids and MTX. Introduction of tacrolimus led to complete remission of the disease in a patient and partial control in the other. Literature review was done which revealed ten patients with JDM who were treated with tacrolimus with encouraging results in the form of significant reduction in the cutaneous and muscle disease activity. Tacrolimus is an useful drug in the management of refractory JDM.

Cite

CITATION STYLE

APA

Rao, A. P., Kolli, V., Rajarathinam, I., & Raghuram, J. (2020, December 1). Tacrolimus in refractory juvenile dermatomyositis: Case report and review of literature. Indian Journal of Rheumatology. Wolters Kluwer Medknow Publications. https://doi.org/10.4103/injr.injr_128_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free